Anthropometric, metabolic, and reproductive outcomes of patients with central precocious puberty treated with leuprorelin acetate 3-month depot (11.25mg).

Abstract

Longer-acting gonadotropin-releasing hormone analogs (GnRHa) have been widely used for central precocious puberty (CPP) treatment. However, the follow-up of patients after this treatment are still scarce. Our aim was to describe anthropometric, metabolic, and reproductive follow-up of CPP patients after treatment with leuprorelin acetate 3-month depot (11.25 mg). Twenty-two female patients with idiopathic CPP were treated with leuprorelin acetate 3-month depot (11.25mg). Their medical records were retrospectively evaluated regarding clinical, hormonal, and imaging aspects before, during, and after GnRHa treatment until adult height (AH). At the diagnosis of CPP, the mean chronological age (CA) was 8.2±1.13year, and mean bone age (BA) was 10.4±1.4year. Mean height SDS at the start and the end of GnRHa treatment was 1.6±0.8 and 1.3±0.9, respectively. The mean duration of GnRHa treatment was 2.8±0.8year. Mean predicted adult heights (PAH) at the start and the end of GnRH treatment was 153.2±8.6 and 164.4±7.3cm, respectively (p<0.05). The mean AH was 163.2±6.2cm (mean SDS: 0.1±1). All patients were within their target height (TH) range. There was a decrease in the percentage of overweight and obesity from the diagnosis until AH (39-19% p>0.05). At the AH, the insulin resistance and high LDL levels were identified in 3/17 patients (17.6%) and 2/21 patients (9.5%), respectively. The mean CA of menarche was 12.2±0.5years. At the AH, PCOS was diagnosed in one patient (4.8%). Long-term anthropometric, metabolic, and reproductive follow-up of patients with CPP treated with longer-acting GnRHa revealed effectivity, safety, and favorable outcomes.